Physician profile
Amanda Reyes
NPI 1700445772
$2,366.41
in general payments reported to CMS, 2019-2025
12 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $825 · 2022: $54.07 · 2023: $303 · 2024: $184 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669 · Entertainment: $43.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.57 |
| Entertainment | $43.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $512.20 | 2019-2025 | Acuvue |
| The Walman Optical Company | $350.00 | 2020 | |
| Optos, INC. | $314.25 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $279.51 | 2023-2024 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $248.71 | 2019 | |
| Coopervision INC. | $169.13 | 2020-2025 | Biofinity Contact Lens |
| Sun Pharmaceutical Industries INC. | $118.43 | 2020 | |
| Maculogix, INC. | $114.61 | 2020 | |
| Aerie Pharmaceuticals, INC. | $112.92 | 2019 | |
| Rxsight INC | $82.55 | 2024-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Topcon Healthcare, INC. | $64.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.